Pharmaceutical Safety Review • Low Interaction Classification
Clinical Review Prescription Drug Interactions & CYP450 Profile
Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.
Absolute Clinical Contraindications
- Severe pre-existing renal disease (eGFR < 30) requiring fluid restriction
Reported Clinical Adverse Events
- Intracellular water retention (1.0 - 2.0 kg)
- Mild GI distress if consumed with insufficient water
Hepatic Cytochrome P450 (CYP) & Transporter Pathways
Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:
- CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
- Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
- Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (Intramuscular saturation washout: 4 – 6 weeks).